StocksFundsScreenerSectorsWatchlists
TFFP

TFFP - TFF Pharmaceuticals Inc Stock Price, Fair Value and News

6.05USD-0.54 (-8.19%)Market Closed

Market Summary

TFFP
USD6.05-0.54
Market Closed
-8.19%

TFFP Stock Price

View Fullscreen

TFFP RSI Chart

TFFP Valuation

Market Cap

14.3M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

19.54

Price/Free Cashflow

-0.89

TFFP Price/Sales (Trailing)

TFFP Profitability

Return on Equity

-222.05%

Return on Assets

-176.62%

Free Cashflow Yield

-112.51%

TFFP Fundamentals

TFFP Revenue

Revenue (TTM)

733.9K

Rev. Growth (Yr)

-63.45%

Rev. Growth (Qtr)

-51.3%

TFFP Earnings

Earnings (TTM)

-21.2M

Earnings Growth (Yr)

35.41%

Earnings Growth (Qtr)

-8.01%

Breaking Down TFFP Revenue

Last 7 days

-17.9%

Last 30 days

2.5%

Last 90 days

-13.8%

Trailing 12 Months

784.4%

How does TFFP drawdown profile look like?

TFFP Financial Health

Current Ratio

3.13

TFFP Investor Care

Shares Dilution (1Y)

63.71%

Diluted EPS (TTM)

-11.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023479.8K785.1K932.3K733.9K
2022131.3K157.4K195.0K495.8K
202100088.2K

Tracking the Latest Insider Buys and Sells of TFF Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 16, 2023
carlson capital l p
sold
-391
0.3916
-1,000
-
Aug 15, 2023
rocamboli stephen
bought
5,000
0.25
20,000
-
Aug 15, 2023
coleman kirk allen
bought
5,000
0.25
20,000
chief financial officer
Aug 15, 2023
mills robert s
bought
10,000
0.25
40,000
-
Aug 15, 2023
mikhak zamaneh
bought
30,000
0.25
120,000
chief medical officer
Aug 15, 2023
carlson capital l p
sold
-94,041
0.4374
-215,000
-
Aug 15, 2023
roberts brandi
bought
5,000
0.25
20,000
-
Aug 15, 2023
weisman harlan f
bought
150,000
0.25
600,000
president and ceo
Mar 10, 2023
rocamboli stephen
bought
10,432
0.8025
13,000
-
Mar 10, 2023
weisman harlan f
bought
131,835
0.8789
150,000
president and ceo

1–10 of 50

Which funds bought or sold TFFP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
sold off
-100
-296,409
-
-%
Mar 11, 2024
VANGUARD GROUP INC
new
-
237,788
237,788
-%
Feb 28, 2024
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO
sold off
-100
-8,000
-
-%
Feb 28, 2024
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO
new
-
6,000
6,000
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-6,000
-
-%
Feb 16, 2024
DRW Securities, LLC
sold off
-100
-350,000
-
-%
Feb 16, 2024
DRW Securities, LLC
new
-
280,800
280,800
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-878
-
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
sold off
-100
-483
-
-%
Feb 14, 2024
STATE STREET CORP
sold off
-100
-24,475
-
-%

1–10 of 50

Are Funds Buying or Selling TFFP?

Are funds buying TFFP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TFFP
No. of Funds

Unveiling TFF Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
lytton laurence w
0.1%
11,900
SC 13G/A
Feb 14, 2023
lung therapeutics, inc.
2.1%
773,000
SC 13G/A
Feb 13, 2023
lytton laurence w
8.4%
3,125,722
SC 13G/A
Feb 09, 2023
carlson capital l p
5.1%
1,842,000
SC 13G/A
Nov 28, 2022
carlson capital l p
6.2%
2,194,000
SC 13G
Nov 23, 2022
lytton laurence w
8.8%
3,137,641
SC 13G
Feb 14, 2022
lung therapeutics, inc.
8.81%
2,235,000
SC 13G/A
Feb 14, 2022
corriente advisors, llc
0.0%
0
SC 13G/A
Feb 14, 2022
nantahala capital management, llc
0%
0
SC 13G/A
Feb 16, 2021
corriente advisors, llc
6.07%
1,350,000
SC 13G

Recent SEC filings of TFF Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Mar 28, 2024
8-K
Current Report
Mar 28, 2024
10-K
Annual Report
Mar 27, 2024
8-K
Current Report
Mar 22, 2024
8-K
Current Report
Mar 22, 2024
424B5
Prospectus Filed
Feb 14, 2024
SC 13G/A
Major Ownership Report
Dec 19, 2023
8-K
Current Report

Peers (Alternatives to TFF Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.7B
6.8B
10.47% -29.37%
-8.64
5.95
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.8B
1.8B
-5.20% -21.33%
-42.76
10.3
76.23% 61.08%
16.5B
2.4B
-4.27% -3.75%
98.3
6.81
15.42% 18.43%
12.8B
3.7B
-5.97% -18.88%
21.4
3.46
8.87% 75.42%
MID-CAP
7.1B
396.6M
-14.15% -6.74%
-13.41
17.87
425.83% 18.94%
5.4B
-
-9.06% 107.52%
-8.32
60.35
54.84% -34.79%
3.8B
270.6M
1.09% 28.79%
-15.8
13.97
440.80% -27.84%
3.5B
240.7M
-9.47% 17.74%
-11.94
14.72
-1.03% -92.09%
3.0B
726.4M
-25.38% 1.37%
-49.71
4.19
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
13.53% -1.12%
26.31
4.72
85.90% -14.05%
669.0M
983.7M
-9.64% -20.86%
-1.23
0.68
-50.36% 17.16%
411.7M
881.7K
52.39% 472.85%
-9.23
466.16
-77.61% -5.33%
324.4M
4.9M
76.14% 20.49%
-2.4
66.66
-54.97% 51.72%
14.1M
2.1M
238.33% 93.33%
-0.52
2.14
-13.45% 66.37%

TFF Pharmaceuticals Inc News

Latest updates
InvestorPlace • 43 minutes ago
InvestorsObserver • 26 Mar 2024 • 05:54 pm
Investing.com • 20 Mar 2024 • 05:07 pm
Yahoo Finance • 3 months ago

TFF Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue-51.3%11423533351.0031388.0028.0067.0012.0050.002.0024.00
Operating Expenses17.8%5,4834,6555,3527,1387,6947,3688,7808,45110,1088,7285,1137,926
  S&GA Expenses10.6%2,5092,2692,6703,1193,5603,3423,6783,2133,1882,3882,3512,647
  R&D Expenses24.6%2,9742,3872,682-4,1214,0265,1025,2626,9206,3402,7625,278
Interest Expenses---36.0035.008.006.006.007.0010.0012.0014.0015.00
Net Income-8.0%-4,762-4,409-5,020-7,051-7,373-7,274-8,746-8,376-10,049-8,678-4,655-7,654
Net Income Margin-13.1%-28.95*-25.59*-34.03*-63.45*-64.08*-176.63*-227.72*-241.92*-352.07*---
Free Cashflow-43.4%-4,284-2,988-4,599-4,506-7,843-8,156-5,509-7,383-11,010-7,333-6,014-6,067
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q42019Q32018Q4
Assets-19.2%12.0015.0014.0018.0024.0020.0028.0034.0041.0049.0057.0061.0039.0043.0029.0011.0010.00
  Current Assets-30.3%8.0011.009.0014.0019.0017.0025.0032.0039.0047.0055.0060.0038.0042.0029.0011.0010.00
    Cash Equivalents-43.5%5.0010.008.0012.0017.0013.0021.0026.0034.0045.0052.0058.0035.0042.0028.0011.0010.00
  Net PPE-3.1%2.002.002.002.003.003.002.002.002.002.002.002.001.001.00---
Liabilities106.0%2.001.001.002.001.002.004.002.002.002.002.002.001.002.002.002.001.00
  Current Liabilities112.7%2.001.001.002.001.002.004.00-2.00---1.002.000.00-1.00
Shareholder's Equity-30.1%10.0014.0012.0017.0023.0018.0024.0032.0039.0048.0056.0060.0037.0042.0028.00--
  Retained Earnings-4.2%-118-113-109-104-97.09-89.72-82.44-73.69-65.32-55.27-46.59-41.93-34.28-28.38-15.71-11.05-3.84
  Additional Paid-In Capital0.5%12812712212112010810610510410310210272.0070.0043.000.001.00
Shares Outstanding0.2%2.002.001.001.001.001.001.001.001.001.001.001.001.00----
Float-------139---229------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-42.4%-4,238-2,976-4,458-4,365-7,701-7,379-5,014-7,246-10,883-7,191-5,890-5,591-6,232-4,255-3,774-2,352-4,306-3,071-1,722-2,115-
  Share Based Compensation-24.0%5827668267529239561,1951,1789218577411,030920546295426211-229486121-
Cashflow From Investing-266.7%-46.39-12.65---141-777-495-137-126-141-124-476---------
Cashflow From Financing-100.0%567*5,090-59.23-17.9211,336431----26.0028,859714---21,851-10.17---

TFFP Income Statement

2023-09-30
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Grant revenue$ 234,763$ 87,586$ 619,543$ 183,025
Operating expenses:    
Research and development2,386,7074,025,9409,087,26414,360,293
General and administrative2,268,6563,342,2668,058,23510,238,744
Total operating expenses4,655,3637,368,20617,145,49924,599,037
Loss from operations(4,420,600)(7,280,620)(16,525,956)(24,416,012)
Other income (expense):    
Interest income88,8106,119160,00919,184
Change in fair value of note receivable(77,454)(114,870)
Total other income, net11,3566,11945,13919,184
Net loss$ (4,409,244)$ (7,274,501)$ (16,480,817)$ (24,396,828)
Net loss per share, basic (in Dollars per share)$ (0.09)$ (0.29)$ (0.41)$ (0.96)
Weighted average common shares outstanding, basic (in Shares)47,441,69325,451,69139,983,82525,399,352
Other comprehensive loss:    
Foreign currency translation adjustments$ (38,182)$ (103,226)$ (64,417)$ (161,426)
Comprehensive loss$ (4,447,426)$ (7,377,727)$ (16,545,234)$ (24,558,254)

TFFP Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 9,725,755$ 16,612,315
Research and development tax incentive receivable361,485186,507
Prepaid assets and other current assets805,6592,226,344
Total current assets10,892,89919,025,166
Operating lease right-of-use asset, net139,230196,044
Property and equipment, net2,064,3543,078,342
Note receivable - Augmenta1,781,0001,812,975
Other assets7,6887,688
Total assets14,885,17124,120,215
Current liabilities:  
Accounts payable983,287919,607
Accrued compensation4,430
Deferred research grant revenue76,000126,000
Current portion of operating lease liability82,72580,625
Total current liabilities1,142,0121,130,662
Operating lease liability, net of current portion52,230110,094
Total liabilities1,194,2421,240,756
Commitments and contingencies (see Note 4)
Stockholders’ equity:  
Common stock; $0.001 par value, 90,000,000 shares and 45,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; 59,133,574 and 36,193,085 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively59,13436,193
Additional paid-in capital127,404,746120,070,983
Accumulated other comprehensive loss(203,712)(139,295)
Accumulated deficit(113,569,239)(97,088,422)
Total stockholders’ equity13,690,92922,879,459
Total liabilities and stockholders’ equity$ 14,885,171$ 24,120,215
TFFP
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.
 CEO
 WEBSITEtffpharma.com
 EMPLOYEES15

TFF Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for TFF Pharmaceuticals Inc? What does TFFP stand for in stocks?

TFFP is the stock ticker symbol of TFF Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TFF Pharmaceuticals Inc (TFFP)?

As of Thu Mar 28 2024, market cap of TFF Pharmaceuticals Inc is 14.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TFFP stock?

You can check TFFP's fair value in chart for subscribers.

What is the fair value of TFFP stock?

You can check TFFP's fair value in chart for subscribers. The fair value of TFF Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TFF Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TFFP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TFF Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TFFP is over valued or under valued. Whether TFF Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact TFF Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TFFP.

What is TFF Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Mar 28 2024, TFFP's PE ratio (Price to Earnings) is -0.6 and Price to Sales (PS) ratio is 15.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TFFP PE ratio will change depending on the future growth rate expectations of investors.